Subcutaneous Daratumumab for Light Chain Amyloidosis: Efstathios Kastritis, MD
Keira Smith
Expert Analysis
Recently, the FDA approved subcutaneous daratumumab in combination with bortezomib/cyclophosphamide/dexamethasone (VCd) for the treatment of patients with newly diagnosed amyloid light chain (AL) amyloidosis. In this interview, Efstathios Kastritis, MD, Associate Professor of Clinical Therapeutics at the National and Kapodistrian University of...
Kohei Shitara, MD: Fam-Trastuzumab Deruxtecan-Nxki for Gastric Cancer
Emily Levitch
Expert Analysis
Fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) has recently been FDA approved for the treatment of adult patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal adenocarcinoma previously treated with a trastuzumab-based regimen. In this interview with i3 Health, Kohei Shitara, MD, Chief of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, and lead investigator of the phase 3 DESTINY-Gastric01 trial, on which the approval was based, shares his insights on this approval, on the challenges of treating this patient population, and on the future of treatment for patients with gastric or gastroesophageal adenocarcinoma.
Understanding and Reducing Regional Variation in Prostate Cancer Surveillance: Samuel L. Washington III, MD, MAS
Keira Smith
Expert Analysis
In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In this interview with i3 Health, Samuel L. Washington III, MD, MAS, Assistant Professor of Urology at the University of California San Francisco and th...
Neal Shore, MD, FACS: Relugolix Approval for Advanced Prostate Cancer
Keira Smith
Expert Analysis
Relugolix (OrgovyxTM, Myovant Sciences) was recently FDA approved as the first oral hormone therapy for patients with advanced prostate cancer. In this interview, Neal Shore, MD, FACS, Medical Director of the Carolina Urologic Research Center and lead investigator of the HERO trial, on which the approval was based, speaks with i3 Health about the a...
Roy Herbst, MD, PhD: Adjuvant Osimertinib for EGFR-Mutated Non-Small Cell Lung Cancer
Keira Smith
Expert Analysis
Recently, the FDA approved osimertinib (Tagrisso®, AstraZeneca) as the first adjuvant therapy for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In this interview, Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and lead investigator of th...
How Delaying Cancer Treatment Impacts Survival: Eugene Cone, MD
Keira Smith
Expert Analysis
In a study published this past week in JAMA Network Open, Eugene Cone, MD, and colleagues found that a longer time to treatment initiation negatively impacts survival in patients with breast, prostate, colon, and lung cancers, a finding that is particularly relevant with the deferral of treatment during the COVID-19 pandemic. In this interview, Dr....
Jaume Mora, MD, PhD: Naxitamab Approval for High-Risk Neuroblastoma in the Bone or Bone Marrow
Keira Smith
Expert Analysis
Recently, the FDA approved naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow. In this interview, Jaume Mora, MD, PhD, Scientific Director of Oncology and Hematology at Sant Joan de Déu Barcelona Children's Hospital and lead...
Thomas Hope, MD: Gallium 68 PSMA-11 Approval for PSMA-Targeted PET Imaging of Prostate Cancer
Keira Smith
Expert Analysis
The FDA recently approved gallium (Ga) 68 PSMA-11, a radioactive diagnostic agent, for prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging of patients with recurrent prostate cancer. Ga 68 PSMA-11, the approval of which was granted to the University of California San Francisco (UCSF) and the University of C...
Hagop Kantarjian, MD: Inotuzumab Ozogamicin for Relapsed/Refractory Ph-Positive Acute Lymphoblastic Leukemia
Keira Smith
Expert Analysis
Among patients with relapsed/refractory acute lymphoblastic leukemia (ALL), those with Philadelphia chromosome (Ph)-positive disease experience a higher rate of relapse and poorer chances of long-term survival. According to results of the phase 3 INO-VATE trial recently published in Cancer, inotuzumab ozogamicin, a humanized anti-CD22 monoclonal an...
Vitamin D Supplements for Reducing Advanced Cancer Risk: Paulette Chandler, MD, MPH
Keira Smith
Expert Analysis
In a study recently published in JAMA Network Open, a team of investigators led by Paulette Chandler, MD, MPH, found that vitamin D supplementation is associated with a decreased risk of developing advanced cancer, particularly among individuals with a normal body mass index (BMI). In this interview with i3 Health, Dr. Chandler, an Assistant Profes...
Atezolizumab for Previously Treated Non-Small Cell Lung Cancer: Julien Mazières, MD, PhD
Keira Smith
Expert Analysis
For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that ate...
Paul Sargos, MD on Adjuvant RT versus Salvage RT for Prostate Cancer
Emily Levitch
Expert Analysis
Results of a new study presented at American Society of Radiation Oncology (ASTRO) 2020 reveal that adjuvant radiotherapy (aRT) significantly increased the risk of late toxicity compared with salvage radiotherapy (sRT). Lead author of the study, Paul Sargos, MD, discusses the significance of these results in addition to advice for community oncolog...
Nivolumab/Ipilimumab for Malignant Pleural Mesothelioma: Paul Baas, MD, PhD
Sarah Williams, MAT
Expert Analysis
The FDA recently approved nivolumab/ipilimumab for the first-line treatment of malignant pleural mesothelioma, marking the second FDA approval for this condition and the first approval in the past 16 years. In this interview, Paul Baas, MD, PhD, principal investigator of the CheckMate 743 trial (NCT02899299), on which the approval was based, speaks...
Ming Shi, MD, PhD: HAIC/FOLFOX Effective for Hepatocellular Carcinoma
Emily Levitch
Expert Analysis
A recent study presented by Ming Shi, MD, PhD and colleagues at ESMO Virtual Congress 2020 found that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yield more effective results in patients with unresectable hepatocellular carcinoma (HCC) compared with transarterial chemoembolization (TACE). In...
Antifungal Prophylaxis for Hematologic Malignancies: Yuan Wan, MD, PhD
Keira Smith
Expert Analysis
While antifungal prophylaxis can effectively prevent invasive fungal infections in patients with hematologic diseases, there is no consensus on which prophylactic agents provide the greatest benefit for different patient populations. In a meta-analysis recently published in JAMA Network Open, a team of researchers found that among antifungal prophy...
Modern Radiation Therapy Doses for Early-Stage Hodgkin Lymphoma: Chelsea Pinnix, MD, PhD
Keira Smith
Expert Analysis
While radiation therapy is an effective treatment for patients with early-stage favorable Hodgkin lymphoma, it also poses a risk of long-term toxicity to the surrounding organs and tissue. In a study recently published in JAMA Network Open, a team of researchers led by first author Chelsea Pinnix, MD, PhD, of MD Anderson Cancer Center, found that c...
Nivolumab/Ipilimumab for Advanced Renal Cell Carcinoma: Meredith Regan, ScD
Keira Smith
Expert Analysis
Patients with advanced renal cell carcinoma (RCC) who receive combination PD-1/CTLA-4 blockade can experience periods of durable benefit and toxicity after treatment discontinuation. According to results of the phase 3 CheckMate 214 trial presented by Meredith Regan, ScD, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, ni...
Nivolumab Plus Chemotherapy for Gastric/Gastroesophageal Junction Cancer: Kohei Shitara, MD
Sarah Williams, MAT
Expert Analysis
In advanced gastric cancer and gastroesophageal junction cancer, treatment options remain limited. Results of the phase 3 CheckMate 649 and phase 2/3 ATTRACTION-4 studies, both of which investigated chemotherapy with or without nivolumab in patients with previously untreated unresectable, advanced, or recurrent gastric/gastroesophageal junction (G/...
Neoadjuvant Ipilimumab/Nivolumab for Locally Advanced/Oligometastatic Melanoma: Emilia Cocorocchio, MD
Keira Smith
Expert Analysis
With high rates of metastasis and progression, locally advanced/oligometastatic melanoma is a challenging disease to treat. According to results of a trial recently presented at the European Medical Society for Oncology (ESMO) Virtual Congress, neoadjuvant ipilimumab/nivolumab is a safe and effective treatment for patients with this disease. In thi...
Daratumumab/Carfilzomib/Dexamethasone for Multiple Myeloma: Meletios A. Dimopoulos, MD
Sarah Williams, MAT
Expert Analysis
Recently, the FDA approved a new treatment for multiple myeloma previously treated with one to three lines of therapy: daratumumab (Darzalex®, Janssen) in combination with carfilzomib and dexamethasone. In this interview, Meletios Dimopoulos, MD, principal investigator of the phase 3 CANDOR trial, which served as the basis for the approval, speaks ...

Copyright © 2022 Oncology Data Advisor. All rights reserved.